Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in the Multidisciplinary Management of Morbidly Adherent Placenta.


Journal

The Israel Medical Association journal : IMAJ
ISSN: 1565-1088
Titre abrégé: Isr Med Assoc J
Pays: Israel
ID NLM: 100930740

Informations de publication

Date de publication:
Jul 2023
Historique:
medline: 19 7 2023
pubmed: 18 7 2023
entrez: 18 7 2023
Statut: ppublish

Résumé

Morbidly adherent placentation (MAP) increases the risk for obstetric hemorrhage. Cesarean hysterectomy is the prevalent perioperative approach. Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a minimally invasive and relatively simple endovascular procedure to temporarily occlude the aorta and control below diaphragm bleeding in trauma. It has been effectively used to reduce obstetric hemorrhage. To evaluate whether REBOA during cesarean delivery (CD) in women with morbidly adherent placentation is a safe and effective treatment modality. We introduced REBOA for CD with antepartum diagnosis of MAP in 2019 and compared these patients (RG) to a standard approach group (SAG) treated in our center over the preceding year, as a control. All relevant data were collected from patient electronic files. Estimated blood loss and transfusion rates were significantly higher in SAG; 54.5% of SAG patients received four RBC units or more vs. one administered in RG. No fresh frozen plasma, cryoprecipitate, or platelets were administered in RG vs. mean 3.63, 6, and 3.62 units, respectively in SAG. Ten SAG patients (90.9%) underwent hysterectomy vs. 3 RG patients (30%). Five SAG patients (45%) required post-surgical intensive care unit (ICU) admission vs. no RG patients. Bladder injury occurred in five SAG cases (45%) vs. 2 RG (20%). One RG patient had a thromboembolic event. Perioperative lactate levels were significantly higher in SAG patients. Use of REBOA during CD in women with MAP is safe and effective in preventing massive bleeding, reducing the rate of hysterectomy, and improving patient outcome.

Sections du résumé

BACKGROUND BACKGROUND
Morbidly adherent placentation (MAP) increases the risk for obstetric hemorrhage. Cesarean hysterectomy is the prevalent perioperative approach. Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a minimally invasive and relatively simple endovascular procedure to temporarily occlude the aorta and control below diaphragm bleeding in trauma. It has been effectively used to reduce obstetric hemorrhage.
OBJECTIVES OBJECTIVE
To evaluate whether REBOA during cesarean delivery (CD) in women with morbidly adherent placentation is a safe and effective treatment modality.
METHODS METHODS
We introduced REBOA for CD with antepartum diagnosis of MAP in 2019 and compared these patients (RG) to a standard approach group (SAG) treated in our center over the preceding year, as a control. All relevant data were collected from patient electronic files.
RESULTS RESULTS
Estimated blood loss and transfusion rates were significantly higher in SAG; 54.5% of SAG patients received four RBC units or more vs. one administered in RG. No fresh frozen plasma, cryoprecipitate, or platelets were administered in RG vs. mean 3.63, 6, and 3.62 units, respectively in SAG. Ten SAG patients (90.9%) underwent hysterectomy vs. 3 RG patients (30%). Five SAG patients (45%) required post-surgical intensive care unit (ICU) admission vs. no RG patients. Bladder injury occurred in five SAG cases (45%) vs. 2 RG (20%). One RG patient had a thromboembolic event. Perioperative lactate levels were significantly higher in SAG patients.
CONCLUSIONS CONCLUSIONS
Use of REBOA during CD in women with MAP is safe and effective in preventing massive bleeding, reducing the rate of hysterectomy, and improving patient outcome.

Identifiants

pubmed: 37461170

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

462-467

Auteurs

Alexander Ioscovich (A)

Department of Anesthesiology, Perioperative Medicine and Pain Treatment, Shaare Zedek Medical Center, affilliated with the Hebrew University of Jerusalem, Israel.

Dmitry Greenman (D)

Department of Anesthesiology, Perioperative Medicine and Pain Treatment, Shaare Zedek Medical Center, affilliated with the Hebrew University of Jerusalem, Israel.

Ilya Goldin (I)

Vascular Surgery Unit, Shaare Zedek Medical Center, affilliated with the Hebrew University of Jerusalem, Israel.

Sorina Grisaru-Granovsky (S)

Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, affilliated with the Hebrew University of Jerusalem, Israel.

Yaacov Gozal (Y)

Department of Anesthesiology, Perioperative Medicine and Pain Treatment, Shaare Zedek Medical Center, affilliated with the Hebrew University of Jerusalem, Israel.

Boris Zukerman (B)

Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, affilliated with the Hebrew University of Jerusalem, Israel.

Fayez Khatib (F)

Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, affilliated with the Hebrew University of Jerusalem, Israel.

Aharon Tevet (A)

Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, affilliated with the Hebrew University of Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH